Acadia Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-12.3%projected annual EPS growth
Analyst Coverage
20analysts covering
FY Revenue (est.)
$1.3Bnext fiscal year
FY EPS (est.)
$0.60next fiscal year
Monitoring Framework
Key Performance Indicators
DAYBUE Net Product Sales Quarterly101MTarget: 460 million to 490 million USD (Full Year 2026 Guidance)
NUPLAZID Net Product Sales Quarterly167MTarget: 760 million to 790 million USD (Full Year 2026 Guidance)
Total GAAP Revenues Quarterly268MTarget: 1.22 billion to 1.28 billion USD (Full Year 2026 Guidance)
Watch Items
- Phase 2 remlifanserin (ACP-204) study readout in Alzheimer's disease psychosisTrigger: Topline results expected between August and October 2026Action: Evaluate efficacy (powered for 0.4 effect size) and safety profile to determine Phase 3 trial design and regulatory pathway.
- Trofinetide (DAYBUE) clinical trial in JapanTrigger: Topline results expected between September and November 2026Action: Assess potential for international expansion and regulatory filings in the Japanese market.
- European Medicines Agency (EMA) CHMP re-examination for trofinetideTrigger: Formal request for re-examination following negative opinion in March 2026Action: Monitor regulatory feedback and adjust European commercialization timeline and peak sales models accordingly.
Research as of 19 Jun 2026